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Abstract
Thrombotic microangiopathy (TMA) is characterised by abnormalities in the walls of arterioles and capillaries, precipitated by hereditary or 
acquired characteristics, and culminating in microvascular thrombosis because of dysregulated complement activity. A number of drugs can 
precipitate TMA, including vascular endothelial growth factor (VEGF) inhibitors, because of their effects on endothelial repair. Pazopanib is 
a VEGF inhibitor used for the treatment of renal cell carcinoma (RCC); it is uncommonly associated with TMA. A 52-year-old male, 5 years 
post his second kidney transplant secondary to immunoglobulin (Ig) A nephropathy, presented with hypertension, fluid overload, and worsening 
graft function (peak creatinine 275 µmol/L, baseline 130–160 µmol/L) and nephrotic range proteinuria 2 months after commencing pazopanib 
for metastatic RCC. His maintenance immunosuppression included ciclosporin, mycophenolate, and prednisolone. Haematological parameters 
were unremarkable. Allograft biopsy demonstrated glomerular and arteriolar changes consistent with chronic active TMA, with overlying fea-
tures of borderline cellular rejection. He was treated with intravenous methylprednisolone 250 mg for 3 days and commenced on irbesartan 75 
mg daily. Drug-induced TMA from pazopanib was suspected, particularly given the documented association with other tyrosine kinase inhib-
itors (TKIs). In consultation with his medical oncologist, pazopanib was ceased, and an alternate TKI cabozantinib was commenced. Serum 
creatinine remained <200 µmol/L 3 months after admission. This is the first reported biopsy-proven case of TMA attributed to pazopanib in 
a kidney transplant recipient. With increasing clinical indications for and availability of TKIs, clinicians need to be aware of their association 
with TMA events in kidney transplant recipients, who are already susceptible to TMA due to abnormal vasculature, infectious triggers, isch-
aemia-reperfusion injury, and use of calcineurin inhibitor.
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Thrombotic microangiopathy (TMA) is characterised by 
abnormalities in the walls of arterioles and capillaries, 
culminating in microvascular thrombosis. Primary TMA 
syndromes are divided into hereditary, because of 
ADAMTS13 deficiency, or mutations affecting complement, 
metabolic, or coagulation pathways; and acquired, because 
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of autoantibody inhibition of ADAMTS13, Shiga toxae-
mia, drug-mediated (either toxicity or immune reaction), and 
complement-mediated due to antibody inhibition of factor 
H activity (1). 
The disease is usually characterised by microangiopathic 
haemolytic anaemia, which is associated with throm-
bocytopenia (2). The pathophysiology involves plate-
let consumption through the formation of  intravascular 
thrombi. Erythrocytes become fragmented as they traverse 
the microthrombi. This is manifested as schistocytes on 
blood film and evidence of  non-autoimmune intravascular 
haemolysis, with raised bilirubin, lactate dehydrogenase 
and reticulocyte count; low haptoglobin; and a negative 
Coombs test (2). 
Drug-induced TMA (DITMA) involves either a comple-
ment-mediated process with the formation of drug-depen-
dent antibodies to platelets, or the drug itself  causing direct 
endothelial toxicity. Herein we report a case of TMA most 
likely induced by pazopanib toxicity, caused by direct inhibi-
tion of vascular endothelial growth factor (VEGF).
Case Report
A 52 year old male kidney transplant recipient who devel-
oped kidney failure secondary to immunoglobulin (Ig) A 
nephropathy, who also had a history of metastatic clear cell 
renal cell carcinoma (ccRCC), on pazopanib, presented with 
acute kidney injury, nephrotic range proteinuria, hyperten-
sion, and fluid overload.
The patient initially received a deceased donor kidney 
transplant in 2001, with subsequent loss of the first allograft 
in 2014 because of chronic rejection, requiring haemodialysis 
in early 2015 until transplantation with a living related donor 
kidney later that year (five mismatches, unsensitised). The 
course of this second graft was immunologically uncompli-
cated with no episodes of rejection, and a stable creatinine 
of 130–160 µmol/L was maintained until the beginning of 
2020. At the time of presentation, his immunosuppression 
regimen consisted of prednisolone 7 mg daily, ciclosporin 
125 mg mane (morning)/100 mg nocte (night), trough level 
consistently <200 µg/L, and mycophenolate mofetil 1000 mg 
twice daily. 
In 2018, a 155mm exophytic tumour of the right native 
kidney was identified following an episode of macroscopic 
haematuria, along with two suspicious pulmonary lesions 
(cT3a, N0, M1). The patient underwent cytoreductive (rad-
ical) nephrectomy and ccRCC was seen on histology. After 
12 months of surveillance, marginal enlargement of pul-
monary lesions was seen, and a new hyperdense exophytic 
soft tissue mass was seen at the head of the pancreas, which 
was thought to represent metastatic disease. Surveillance 
was continued while asymptomatic; however, the next few 
months were complicated by worsening liver function tests 
requiring endoscopic retrograde cholangiopancreatography 
(ERCP). New cerebellar metastases were also identified and 
managed with a posterior fossa craniotomy and short course 
of stereotactic radiotherapy. 
Pazopanib was commenced post-radiotherapy, but this 
was interrupted after 2 months of treatment because of bili-
ary sepsis and the need for a repeat ERCP. He recommenced 
pazopanib in late 2019, at which time baseline creatinine was 
stable at 131 µmol/L.
Over the next 2 months, the patient’s creatinine began to 
drift up, culminating in a hospital admission for hypertension 
(systolic blood pressure >180 mmHg on home sphygmoma-
nometer) and peripheral oedema. He was haemodynami-
cally stable at presentation, with a blood pressure of 156/98 
mmHg (baseline systolic blood pressure <120 mmHg), and 
serum creatinine of 218 µmol/L. 
Ultrasound of the transplant kidney was unremark-
able, including normal intrarenal Dopplers and a patent 
renal vein. Urine microscopy was normal; however, he had 
nephrotic range proteinuria, with a urine protein to creati-
nine ratio of 745 g/mol. He was initially managed with furo-
semide. Nephrotoxins were withheld, including pazopanib.
Owing to lack of improvement in his kidney function, he 
had an allograft biopsy on the third day three of admission, 
which demonstrated glomerular and arteriolar changes of 
chronic active TMA (Figure 1). Eight glomeruli and one 
small artery were sampled. There was one globally sclerosed 
glomerulus and four showing segmental sclerosis with occa-
sional double contours. Most of the remaining glomeruli 
showed changes of thrombotic microangiopathy, including 
intracapillary fibrin deposition, karyorrhectic debris, and 
red cell fragments. Fibrin was also identified within thick-
ened arteriolar intima, confirmed on special staining. Some 
corticomedullary arterioles demonstrated focal onion skin-
ning with myxoid intima, fibrinoid change, karyorrhectic 
debris, and red cell fragments. No arterial involvement was 
seen. Electron microscopy demonstrated thickened glomer-
ular basement membranes with prominent subendothelial 
lucent widening, loss of endothelial fenestrations, and over-
lying podocyte effacement. Widespread mesangial, parame-
sangial, intramembranous, and subendothelial electron 
dense deposits with a vaguely fibrillary substructure were 
also noted (Figure 2). Immunofluorescence demonstrated 
granular and globular subendothelial IgM, C3, and lambda, 
and specks of IgG, IgA, C1q, and kappa within sclerosed 
segments.
Chronic changes included 10–20% tubulointerstitial scar-
ring, 50% segmental glomerulosclerosis, and 12.5% global 
glomerulosclerosis (ci1, ct1, cg0). Borderline T-cell rejec-
tion (t2, i0, ti1) and acute tubular necrosis were also noted 
on biopsy. There were no features that would indicate anti-
body-mediated rejection, and donor-specific antibodies 
(which can precipitate TMA) were not present.
Pazopanib-associated TMA after kidney transplant





Figure 1: Light micrographs of kidney transplant biopsy. (A) Glomerulus with intracapillary fibrin, red cell fragments, and 
karryorhectic debris (hematoxylin and eosin × 40). (B) Segmentally sclerosed glomerulus with double contouring and fibrin 
(silver × 40). (C and D) Arterioles with fibrin, and focal onion skinning with myxoid intima, red cell fragments, and karyorrhexis 
(C: hematoxylin and eosin × 40; D: silver × 40).
Following the results of  the biopsy, the patient was started 
on intravenous methylprednisolone 250 mg for 3 days to 
proactively manage any T-cell rejection. Serum creatinine 
peaked at 275 µmol/L on the fourth day of admission. 
Lactate dehydrogenase was mildly elevated. There were no 
haematological manifestations of TMA (Table 1), includ-
ing absent schistocytes on film, normal platelet count, and 
normal bilirubin. Serum haptoglobin was elevated, which is 
inconsistent with TMA; however, elevated haptoglobin has 
been reported in patients with RCC, which may explain this 
finding (3). ADAMTS13 activity was normal. Shiga toxin 
was not tested for in the absence of diarrhoea; a Coombs 
test was not done in the absence of overt haemolysis. TMA 
was attributed to pazopanib as a diagnosis of  exclusion. 
Atypical haemolytic uraemic syndrome (HUS) was deemed 
less likely, given the absence of haematological manifesta-
tions of TMA.
He was commenced on irbesartan 75 mg and discharged 
with a plan for outpatient optimisation of blood pressure. 
Eculizumab was considered; however, as DITMA was more 
likely than atypical HUS, and because serum creatinine con-
tinued to downtrend (Figure 3), eculizumab was not pur-
sued. A shared decision was made between the patient and 
the nephrology and oncology teams to discontinue pazo-
panib, despite its efficacy in this case, and begin a trial of 
cabozantinib, a different class of multi-tyrosine kinase 
inhibitor with good effectiveness in metastatic ccRCC (4). 
This decision was made due to the patient’s prioritisation of 
maintaining allograft function balanced against oncological 
control, which was based on the considerations that he still 
operated his own business and lived in a rural area. Careful 
monitoring of kidney function was needed, as TMA has also 
been reported in association with cabozantinib (5). Three 
months following discharge, serum creatinine dropped below 
Kalla S. et al.





Figure 2: Electron micrographs of kidney transplant biopsy. (A) Mesangial expansion by increased mesangiocytic processes and 
electron dense deposits. (B and C) Subendothelial lucent widening with loss of endothelial fenestrations, mesangial interposition-
ing, and intramembranous electron-dense deposits. (D) Higher power view of deposits showing vaguely fibrillary substructure.
Table 1: Pertinent investigations on admission and 
discharge.
Investigation Admission Discharge
Haemoglobin 115 g/L 121 g/L
Platelet Count 172 ×109/L 238 ×109/L
Creatinine 218 µmol/L 244 µmol/L
Total Bilirubin 9 µmol/L 9 µmol/L
Lactate Dehydrogenase 393 unit/L 312 unit/L
Haptoglobin — 2.89 g/L
ADAMTS13 Activity — 0.91 IU/mL
Urine ACR 570 g/mol —
Urine PCR 745 g/mol —
Follow-up results were from 2 months post-discharge. ACR: 
albumin–creatinine ratio; PCR: protein–creatinine ratio.
200 µmol/L; however, the patient continued to experience 
nephrotic range proteinuria (Figure 3).
Written informed consent was provided by the patient to 
publish this case report.
Discussion
We report a case of de novo kidney-limited TMA in a kidney 
transplant recipient, presumed secondary to pazopanib, pre-
scribed for the treatment of metastatic ccRCC. This report is 
only the second biopsy-confirmed diagnosis of TMA asso-
ciated with pazopanib, and the only biopsy-confirmed case 
of VEGF inhibitor-associated TMA in a kidney transplant 
recipient of which the authors are aware. We propose that 
TMA developed due to the anti-VEGF effects of pazopanib, 
and was predisposed by other transplant-related factors, 
including chronic use of calcineurin inhibitors.
Thrombotic microangiopathy is a well-known class effect 
of anti-VEGF agents, and there are numerous reports of 
Pazopanib-associated TMA after kidney transplant
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Figure 3: Serum creatinine and trough ciclosporin levels compared against time from admission, and commencement of both 
pazopanib and cabozantinib.
TMA associated with the use of bevacizumab, sunitinib, 
sorafenib, and afibercept (6–8). The most likely mechanism 
of injury is direct VEGF inhibition, which, in the setting of 
high glomerular shear stress, perpetuates endothelial dam-
age, and is conducive to the development of TMA (9, 10). 
Despite this theoretical risk, TMA is rarely reported in asso-
ciation with pazopanib, although proteinuria, hypertension, 
and thrombocytopenia are frequently observed without 
TMA in patients taking pazopanib (11–15). In these cases, 
proteinuria is most likely driven by podocyte effacement and 
exacerbated by concomitant hypertension (16). 
Thrombotic microangiopathy is identified as a potential 
side effect of pazopanib by its manufacturers (17), and has 
been reported in trials combining pazopanib with bevaci-
zumab (18); however, to the best of the authors’ knowledge, 
there are only two published case reports wherein pazopanib 
has been linked to TMA. The first case was of a 31-year-old 
male who had been managed with pazopanib for 8 months 
for rhabdomyosarcoma and presented with nephrotic syn-
drome, and was found to have endothelial damage suggestive 
of TMA on kidney biopsy, without systemic manifestations. 
In this case, pazopanib was suggested as the primary cause 
of TMA, and full recovery was seen following drug cessa-
tion (19). The second case was of a 76-year-old male, who 
was managed with pazopanib for 4 months following RCC 
diagnosis; he presented with acute kidney injury, hyperbiliru-
binaemia, and schistocytes on film, and was diagnosed with 
TMA on clinical grounds. This patient had low ADAMTS13 
activity, which was probably the driving mechanism, rather 
than VEGF inhibition; enzyme activity increased following 
cessation of pazopanib and 1 week of plasmapheresis (20).
Given that the present case report was in a kidney trans-
plant recipient, a number of additional considerations were 
to be made if  attributing TMA to pazopanib. In absolute 
terms, de novo TMA occurs uncommonly in the post-trans-
plant period; its incidence has been reported as 0.8% in 
15,870 kidney transplant recipients, transplanted between 
1998 and 2000, in a retrospective analysis of the United 
States Renal Data System (21). Despite this, TMA is also 
substantially more common in allograft than native kidneys, 
predisposed by abnormal vasculature, ischaemic injury, and 
frequent infectious triggers, and de novo TMA was reported 
in 2.8–13.8% of transplant biopsies across a number of stud-
ies (22). Notwithstanding, a majority of these cases were 
presumedly related to anti-rejection drugs, caused by both 
calcineurin inhibitors, through endothelial damage and 
direct effects that promote platelet aggregation (23), and 
mammalian target of rapamycin (mTOR) inhibitors, which 
have some anti-VEGF properties and cause lower renovascu-
lar and podocyte expression of VEGF (24). As the patient in 
the present case report was taking ciclosporin as part of his 
immunosuppression regimen, it is impossible to rule out that 
the presentation was solely due to the effects of ciclosporin. 
However, this hypothesis was clinically less likely, given the 
patient had been maintained on ciclosporin for many years 
with all recorded trough levels below 200 µg/L in the months 
leading up to TMA diagnosis, and because improvement of 
kidney function following cessation of pazopanib was seen 
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despite ongoing use of ciclosporin. Furthermore, as pazo-
panib was started relatively recently, this supports the pre-
sumption that it was involved in the pathogenesis of TMA. 
The fact that TMA was limited to the kidney is also support-
ive that it developed secondary to VEGF inhibition, as this 
presentation is typical of patients who develop DITMA in 
association with this class of medication (25). 
An interesting finding in this biopsy was the presence of 
widespread mesangial, paramesangial, intramembranous, 
and subendothelial electron dense deposits with vaguely 
fibrillary substructure. Similar electron-dense deposits have 
been reported in association with bevacizumab, attributed 
to serum protein leakage in the context of VEGF inhibi-
tion increasing endothelial permeability (26). A comparable 
mechanism could be involved in this case. The architecture 
of these deposits could be consistent with diabetic fibrillo-
sis, but this is less likely because the patient always had good 
glycaemic control. Cryoglobulin deposition was another 
differential diagnosis. Although this hadn’t been specifically 
investigated, it is less likely given the clinical course.
A feasible consideration in this case is that multiple “hits” 
contributed to the development of TMA (27), whereby endo-
thelial damage caused by ciclosporin was perpetuated by 
VEGF inhibition by pazopanib, leading to unchecked com-
plement activation and platelet aggregation without endothe-
lial recovery, over time causing the development of chronic 
TMA-like changes that were seen on biopsy. Although 
reports of TMA in transplant recipients taking both calci-
neurin and direct VEGF inhibitors are sparse (28, 29), this 
proposed interaction between calcineurin inhibitors and 
VEGF inhibition is supported by a number of studies which 
have reported higher-than-expected incidence of TMA when 
combining calcineurin inhibitors with mTOR inhibitors 
(30–33), as mTOR inhibitors as a class also have anti-VEGF 
properties (34). This observation has potential ramifications 
for patients taking calcineurin inhibitors in conjunction with 
VEGF inhibitors.
Conclusion
This report outlined the first biopsy-proven case of TMA 
attributable to a VEGF inhibitor in a kidney transplant recip-
ient, and the second case of biopsy-proven TMA attributable 
to the use of pazopanib. This case introduces the important 
consideration that combining calcineurin and VEGF inhib-
itors in transplant recipients may increase the likelihood of 
TMA-related events in this already susceptible population. 
This hypothesis is worthy of further investigation.
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